Facing the crisis of drug-resistant germs

Thursday,  Feb. 18 at 1:00 p.m. ET / 10:00 a.m. PT 

The Covid-19 pandemic has shown what happens when we let our guard down against infectious disease, despite years of increasingly loud warnings. So now is the time to heed those same warnings about antibiotic-resistant germs.

But, what can be done? STAT brings together a panel of experts, from policymakers to corporate executives, to chart a path to progress.

Sponsor Introduction

  • Kenneth E. Thorpe, professor of health policy at Emory University and chairman of the Partnership to Fight Infectious Disease

Part 1:  Legislative solutions

It’s obvious that D.C. needs to play a role in fixing this problem. What can be done? Senator Bill Cassidy has some ideas.
  • Senator William Morgan Cassidy (R-LA)
  • Matthew Herper, senior writer, medicine; editorial director of events, STAT (moderator)

Part 2: Defining the problem

Why has this problem been so hard to solve? What are the consequences if we don’t find a solution? An expert discussion.
  • Helen W. Boucher M.D., F.A.C.P., F.I.D.S.A., chief, Division of Geographic Medicine and Infectious Diseases; director, Levy Center for Integrated Management of Antimicrobial Resistance (CIMAR)
  • Evan Loh, M.D., chief executive officer, Paratek
  • Gail R. Hansen, D.V.M., M.P.H., senior consultant, Hansen Consulting LLC
  • Ed Silverman, Pharmalot columnist, senior writer, STAT (moderator)

Sponsored by: